SCHEMBL20135329

SCHEMBL20135329

CC1(c2ccc(C(=O)N3CCC(c4cc(-c5ccc(Cl)cc5)[nH]n4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 2/20 0.41
ADAM17 P78536 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MGLL Q99685 4/20 0.39
MAPT P10636 1/20 0.39
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
KDM5A P29375 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
IP6K1 Q92551 3/20 0.38
IP6K3 Q96PC2 1/20 0.38
IP6K2 Q9UHH9 1/20 0.38
MAPK11 Q15759 2/20 0.37
MAPK14 Q16539 2/20 0.37
FASN P49327 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135328 1.00 ADAMTS5 (0.41) ADAMTS5ADAM17MEN1KMT2AMGLL
SCHEMBL20791692 0.92 ABL1 (0.41) MEN1KMT2AMGLLKDM5ACYP2C9
SCHEMBL20135549 0.89 ADAMTS5 (0.40) ADAMTS5ADAM17MEN1KMT2AMGLL
SCHEMBL20135067 0.81 ADAM17 (0.39) ADAMTS5ADAM17MEN1KMT2ACYP2C9
SCHEMBL20791691 0.79 UBE2M (0.40) ADAMTS5ADAM17MEN1KMT2AMGLL
SCHEMBL20791693 0.79 UBE2M (0.40) ADAMTS5ADAM17MEN1KMT2AMGLL
SCHEMBL20135104 0.77 UBE2M (0.51) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL20135106 0.77 UBE2M (0.51) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL29688835 0.77 UBE2M (0.51) MEN1KMT2AMAPTCYP2C9CYP2C19
SCHEMBL22491380 0.76 MGLL (0.52) MEN1KMT2AMGLLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ADAMTS5 23/4885ADAM17 36/4885MEN1 3735/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ADAMTS5 25/4885ADAM17 39/4885MEN1 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.